16th Aug 2010 07:00
16 August 2010
Source BioScience plc (`Source BioScience', `the Company' or `the Group') Notice of half yearly report
Source BioScience plc , the provider of expert, quality services and products to the healthcare, pharma biotech and life sciences research sectors, will announce its half yearly report for the six months ended 30 June 2010 on Tuesday 24 August 2010.
The Company has experienced good trading conditions in Q2, in line with those previously reported in May for Q1, and the Group continues to trade in line with management expectations.
- ENDS -
For further information, please contact:
Source BioScience plcDr Nick AshManaging DirectorTel: + 44 (0) 115 973 [email protected] CommunicationsNick Rome / Gemma O'HaraTel: + 44 (0) 207 562 3350
www.bishopsgatecommunications.com
Singer Capital Markets Limited (Financial Advisor and Joint Broker)
Shaun Dobson / Claes Sp¥ngTel: +44 (0) 203 205 7500www.singercm.com
Daniel Stewart Securities (Joint Broker)
Martin LampshireTel: +44 (0)207 776 6550www.danielstewart.co.ukAbout Source BioScience:
Source BioScience is a highly focused healthcare and biotechnology company providing diagnostic and screening services to the healthcare community and genetic analyses and biomolecular tools and products to the life science research and pharma biotech sectors.
Its Healthcare operations provide screening and reference laboratory diagnostic testing for cancer and other diseases and additional predictive testing for treatment optimisation for clinicians and patients. Pharma Biotech Services offers support for early stage therapeutic development, offering a 'one-stop shop' from tissue pathology, immunohistochemistry, sophisticated image analysis, biomarker determination and assay development to pharmacogenomics including genotyping and gene expression analysis. The Life Sciences division provides core laboratory research support from conceptualisation to implementation, calling upon a wide range of cutting-edge technology platforms including an online catalogue of biomolecular tools. This incorporates DNA sequencing, whole genome amplification and a comprehensive library of genomic reagents and clones including cDNA and RNAi, as well as facilitating rapid access to high quality antibodies, cell cultures, diagnostic assays for cancer and other genetic testing, and related research tools.
The Group has its headquarters in Nottingham, UK where it operates state of the art reference laboratory facilities, with additional laboratory facilities in London, Cambridge, Oxford and Dublin, Ireland. Source BioScience is CPA, GLP and GCP accredited and is licensed by the Human Tissue Authority.
Further information about Source BioScience can be found at www.sourcebioscience.com.
vendorRelated Shares:
SBS.L